Skip to content

Home - Media - Press releases - 2004    
19 November 2004
CRESTOR™ STOCK EXCHANGE STATEMENT

During the course of testimony yesterday, to the Committee of Finance of the US Senate Hearing on the worldwide withdrawal of VIOXX, Dr David Graham raised the possibility of safety concerns surrounding five other products including AstraZeneca's lipid lowering medicine 'Crestor'.
AstraZeneca has followed up these remarks with speed and diligence. We have been assured today at senior levels in the FDA that there is no concern in relation to 'Crestor's safety and that they have issued a statement explaining that Dr Graham's testimony does not reflect the views of the agency.

To date over 12 million prescriptions have been written for 'Crestor' worldwide and 3.5 million patients have been prescribed the drug. 'Crestor' has been approved in 65 countries worldwide and with the latest information on 'Crestor' patient safety, available as recently as Friday 12 November 2004, (available on www.rosuvastatininformation.com) AstraZeneca is confident in both the safety and the efficacy of 'Crestor'



Further enquiries to:

Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Enquiries:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
AstraZeneca websites
Search
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008